Gillian Cannon
Director/Board Member at CORCEPT THERAPEUTICS INCORPORATED
Net worth: - $ as of 2024-05-30
Network origin in Gillian Cannon first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY.
26
| Subsidiary | Pharmaceuticals: Major | 26 |
| Public Company | Pharmaceuticals: Major | 20 | |
| Public Company | Pharmaceuticals: Major | 19 | |
Affibody AB
 Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden.
6
| Subsidiary | Miscellaneous Commercial Services | 6 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes.
5
| Subsidiary | Financial Conglomerates | 5 |
Edinburgh Innovations Ltd.
 Edinburgh Innovations Ltd. Miscellaneous Commercial ServicesCommercial Services Edinburgh Innovations Ltd. engages in the provision of management service for the University of Edinburgh. The company is headquartered in Edinburgh, the United Kingdom.
2
| Subsidiary | Miscellaneous Commercial Services | 2 |
Alyvant, Inc.
1
| Subsidiary | 1 | |
Merck BioVentures
1
| Subsidiary | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Gillian Cannon via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ALZA CORPORATION | Pharmaceuticals: Major | General Counsel Sales & Marketing | |
| GILEAD SCIENCES, INC. | Biotechnology | Chief Executive Officer Public Communications Contact Investor Relations Contact Chief Tech/Sci/R&D Officer | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| IRIDEX CORPORATION | Medical Specialties | Director of Finance/CFO Director/Board Member | |
| DURECT CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Cellectricon AB
 Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Miscellaneous Commercial Services | Founder Director/Board Member | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Chairman Chief Tech/Sci/R&D Officer Chairman Investor Relations Contact Director/Board Member | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member Director/Board Member | |
| ROIVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Chairman Comptroller/Controller/Auditor Chief Executive Officer President Director of Finance/CFO | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Sales & Marketing | |
| GW PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chief Executive Officer Consultant / Advisor | |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Founder Chief Executive Officer Director/Board Member Director of Finance/CFO Chief Executive Officer | |
Investor Growth Capital AB
 Investor Growth Capital AB Investment ManagersFinance Investor Growth Capital AB (IGC) is a venture capital subsidiary of Investor AB founded in 1968. The firm is headquartered Stockholm, Sweden. | Investment Managers | Private Equity Investor President | |
| The Johns Hopkins University | College/University | Graduate Degree Graduate Degree | |
| Yale University | College/University | Director/Board Member Undergraduate Degree Undergraduate Degree Masters Business Admin Doctorate Degree | |
| University of British Columbia | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Graduate Degree Masters Business Admin | |
| The Pennsylvania State University | College/University | Undergraduate Degree Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| University of California, Davis | College/University | Graduate Degree Corporate Officer/Principal | |
| University of Florida | College/University | Graduate Degree Graduate Degree | |
| Stockholm School of Economics | College/University | Graduate Degree Graduate Degree Masters Business Admin | |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Atlas Antibodies AB
 Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Biotechnology | Founder Director/Board Member Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| Yale School of Medicine | College/University | Doctorate Degree Doctorate Degree | |
| Harvard College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer Chief Operating Officer | |
| TOBIRA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SIO GENE THERAPIES INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member Director/Board Member | |
Axovant Sciences, Inc.
 Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a company that manufactures and distributes pharmaceutical products. The company is based in New York, NY. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer | |
| MYOVANT SCIENCES LTD. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chairman Director/Board Member Director/Board Member | |
| IMMUNOVANT, INC. | Biotechnology | Director/Board Member Director/Board Member Chairman Director/Board Member | |
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| Roivant Social Ventures, Inc. | Director/Board Member Director/Board Member Director/Board Member | ||
Dermavant Sciences Ltd.
 Dermavant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
Immunovant Sciences Ltd.
 Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
Dermavant Sciences, Inc.
 Dermavant Sciences, Inc. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Dermavant Sciences, Inc. develops biological products. The company is based in Raleigh, NC. Todd Zavodnick has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Kriya Therapeutics, Inc.
 Kriya Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kriya Therapeutics, Inc. designs and develops transformative new treatments for prevalent and severe chronic diseases. The company was founded by Shankar Ramaswamy and Roger Jeffs and is headquartered in Redwood City, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Sumitovant Biopharma, Inc.
 Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Chairman Director/Board Member |
Statistics
International
| United States | 35 |
| Sweden | 7 |
| United Kingdom | 7 |
| Canada | 2 |
| France | 2 |
Sectoral
| Health Technology | 32 |
| Consumer Services | 14 |
| Commercial Services | 4 |
| Finance | 3 |
Operational
| Director/Board Member | 420 |
| Corporate Officer/Principal | 167 |
| Independent Dir/Board Member | 127 |
| Chairman | 71 |
| Chief Executive Officer | 63 |
Most connected contacts
| Insiders | |
|---|---|
| Pierre Legault | 45 |
| George Bickerstaff | 37 |
| Frank Torti | 35 |
| Carl Erik Mathias Uhlén | 32 |
| Stig Anders Lindberg | 31 |
| Clarence Machado | 30 |
| Kenneth Ludlum | 24 |
| Berndt A. E. Modig | 23 |
| Erik Walldén | 22 |
| Gregg Alton | 22 |
| Simon Pimstone | 22 |
| Mohammad Azab | 21 |
| David Mahoney | 21 |
| Atul Pande | 20 |
| Mohammed Khoso Baluch | 19 |
- Stock Market
- Insiders
- Gillian Cannon
- Company connections
